文献速递自身免疫性与大疱性皮肤病

利妥昔单抗治疗天疱疮的长期结局

Long-term outcomes of rituximab therapy in pemphigus.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-07-09

该回顾性研究纳入59例天疱疮患者,中位观察104个月,评估利妥昔单抗长期疗效。首次疗程后完全缓解且停药(CRoff)率为39%,追加疗程后升至61%,长期CRoff达27%。复发率首次疗程后63%,后续疗程约40%;再治疗再诱导缓解率94%。基线抗桥粒芯蛋白抗体≤250 U/mL与CRoff显著相关。

要点

  • 首次利妥昔单抗疗程后CRoff率39%,追加疗程可提高至61%。
  • 基线抗桥粒芯蛋白抗体≤250 U/mL预测完全缓解且停药。
  • 复发后再用利妥昔单抗再诱导缓解率高达94%。

核心结论

  • 基线桥粒芯蛋白特异性抗体水平较低可预测完全缓解且停药。
  • 接受多疗程利妥昔单抗者,首次疗程后完全缓解与良好长期结局相关。
  • 重复利妥昔单抗疗程对复发高度有效并改善总体结局。

研究设计与样本

  • 回顾性研究纳入59例天疱疮患者,均接受利妥昔单抗治疗,中位观察104个月。

主要发现

  • 首次利妥昔单抗疗程后完全缓解且停药(CRoff)率为39%,追加疗程后升至61%,长期CRoff达27%。
  • 首次疗程后复发率63%,后续疗程约40%;首次及后续疗程后中位复发时间均为25个月。
  • 再次利妥昔单抗治疗在94%的病例中再诱导完全缓解。
  • 基线抗桥粒芯蛋白抗体≤250 U/mL与CRoff结局显著相关。
  • 首次疗程诱导完全缓解后复发者比缓解不佳者或无效者更易达到CRoff。

关键数值与推荐

  • CRoff定义:完全缓解且停药。
  • 基线抗桥粒芯蛋白抗体阈值:≤250 U/mL与CRoff显著相关。
  • 首次及后续利妥昔单抗疗程后中位复发时间:25个月。

临床怎么用

  • 基线抗桥粒芯蛋白抗体≤250 U/mL的天疱疮患者可预期较高CRoff概率。
  • 对首次利妥昔单抗疗程后复发者,重复疗程可高效再诱导缓解并改善长期结局。

局限性

  • 回顾性研究设计。
  • 样本量59例。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rituximab induces a rapid remission in most patients with pemphigus. OBJECTIVE: Our aim was to assess the long-term efficacy of rituximab in this disease. METHOD: We conducted a retrospective study of 59 patients with pemphigus treated with rituximab and observed over a median period of 104 months. RESULTS: The rate of complete remission off therapy (CRoff) after the first rituximab cycle was 39%, increasing to 61% with additional rituximab courses. Long-term CRoff was achieved in 27% of patients. The recurrence rate after the first rituximab cycle was 63%, decreasing to approximately 40% with subsequent rituximab cycles. Median time to relapse after the first and subsequent rituximab cycles was 25 months. Renewed rituximab therapy reinduced complete remission in 94% of cases. Baseline anti-desmoglein antibody levels of ≤250 U/mL were significantly associated with the outcome of CRoff. In paired serum samples obtained before the first and six months after the last rituximab therapy, significant reductions of desmoglein-specific autoantibodies were observed. Patients relapsing after a complete remission induced by the first rituximab cycle were more likely to achieve CRoff than patients relapsing after a less favourable outcome and non-responders. There was no significant difference in age, sex, pemphigus subtype, rituximab dosing and disease duration between patients achieving CRoff and those not meeting this end point. CONCLUSIONS: Lower desmoglein-specific antibody levels at baseline were predictive of CRoff. In patients receiving multiple rituximab cycles, complete remission after the first cycle was associated with a favourable long-term outcome. Repeated rituximab courses were highly effective for relapsed disease and improved the overall outcome.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Shimanovich I, Baumann T, Schmidt E, et al. Long-term outcomes of rituximab therapy in pemphigus. J Eur Acad Dermatol Venereol. 2020. PMID: 32367562. doi:10.1111/jdv.16561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。